RUBICON RESEARCH LIMITED Fair Value
RUBICON · Healthcare · Current price ₹1,823
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹95 | 27% ROE fading to 12% over ~3 yrs, on ₹78 book |
| Relative P/E | ₹585 | EPS × 39.1 peer-median P/E |
| Graham floor | ₹162 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹1,898 | Street consensus 12-month target price |
Is RUBICON RESEARCH LIMITED undervalued?
DocStoX estimates the fair value of RUBICON RESEARCH LIMITED at ₹540 per share, versus the current market price of ₹1,823. That puts the stock about -70.4% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹95), Relative P/E (₹585), Graham floor (₹162), Analyst target (₹1,898). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹95 (bear) to ₹540 (base) to ₹1,898 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on RUBICON RESEARCH LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.